Michelle L. Basil - 19 Sep 2022 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
EVP and General Counsel
Signature
/s/ Michelle L. Basil
Issuer symbol
HAE
Transactions as of
19 Sep 2022
Net transactions value
-$531,322
Form type
4
Filing time
21 Sep 2022, 16:50:59 UTC
Previous filing
19 Sep 2022
Next filing
26 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Options Exercise $133,122 +3,464 +9.8% $38.43 38,859 19 Sep 2022 Direct F1, F2
transaction HAE Common Stock Options Exercise $175,429 +4,213 +11% $41.64 43,072 19 Sep 2022 Direct F1, F2
transaction HAE Common Stock Options Exercise $57,192 +1,011 +2.3% $56.57 44,083 19 Sep 2022 Direct F1, F2
transaction HAE Common Stock Sale $897,065 -11,448 -26% $78.36 32,635 19 Sep 2022 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Options Exercise $0 -3,464 -100% $0.000000* 0 19 Sep 2022 Common Stock 3,464 $38.43 Direct F1, F4
transaction HAE Non-qualified Stock Option (Right to Buy) Options Exercise $0 -4,213 -100% $0.000000* 0 19 Sep 2022 Common Stock 4,213 $41.64 Direct F1, F4
transaction HAE Non-qualified Stock Option (Right to Buy) Options Exercise $0 -1,011 -7.5% $0.000000 12,553 19 Sep 2022 Common Stock 1,011 $56.57 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction pursuant to an existing 10b5-1 trading plan.
F2 This number includes unvested restricted stock units ("RSUs") previously reported.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.75, inclusive. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.